Pharmacological Research (Aug 2023)

Malignant function of nuclear factor-kappaB axis in prostate cancer: Molecular interactions and regulation by non-coding RNAs

  • Reyadh R. Al-Rashidi,
  • Sara Abdalrazzaq M. Noraldeen,
  • Ali Kamil Kareem,
  • Aisha Kamal Mahmoud,
  • Wesam R. Kadhum,
  • Andrés Alexis Ramírez-Coronel,
  • Acim Heri Iswanto,
  • Rasha Fadhel Obaid,
  • Abduladheem Turki Jalil,
  • Yasser Fakri Mustafa,
  • Noushin Nabavi,
  • Yuzhuo Wang,
  • Lin Wang

Journal volume & issue
Vol. 194
p. 106775

Abstract

Read online

Prostate carcinoma is a malignant situation that arises from genomic alterations in the prostate, leading to changes in tumorigenesis. The NF-κB pathway modulates various biological mechanisms, including inflammation and immune responses. Dysregulation of NF-κB promotes carcinogenesis, including increased proliferation, invasion, and therapy resistance. As an incurable disease globally, prostate cancer is a significant health concern, and research into genetic mutations and NF-κB function has the efficacy to facilitate the introduction of novel therapies. NF-κB upregulation is observed during prostate cancer progression, resulting in increased cell cycle progression and proliferation rates. Additionally, NF-κB endorses resistance to cell death and enhances the capacity for metastasis, particularly bone metastasis. Overexpression of NF-κB triggers chemoresistance and radio-resistance, and inhibition of NF-κB by anti-tumor compounds can reduce cancer progression. Interestingly, non-coding RNA transcripts can regulate NF-κB level and its nuclear transfer, offering a potential avenue for modulating prostate cancer progression.

Keywords